US EditionPublished • loading... • Updated
ADMA Biologics Inc (ADMA) Stock Analysis: Unveiling A Promising 37% Upside Potential
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
ADMA Biologics Inc (ADMA) Stock Analysis: Unveiling A Promising 37% Upside Potential
ADMA Biologics Inc (NASDAQ: ADMA) presents an intriguing opportunity for investors with its impressive potential upside of 37.28%, as indicated by current analyst ratings. Standing at the intersection of healthcare and biotechnology, ADMA Biologics focuses on the development, manufacturing, and marketing of specialty plasma-derived biologics, catering to the treatment of immune deficiencies and infectious diseases globally. Its robust product li…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
